Cargando…

Limitation and challenges in using pancreatic cancer‐derived organoids as a preclinical tool

Detalles Bibliográficos
Autores principales:	Fraunhoffer, Nicolas A., Abuelafia, Analía Meilerman, Dusetti, Nelson, Iovanna, Juan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2022
Materias:	Letters to the Editor
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9558692/ https://www.ncbi.nlm.nih.gov/pubmed/35848462 http://dx.doi.org/10.1002/cac2.12335

Ejemplares similares

Inhibition of glucuronidation in pancreatic cancer improves gemcitabine anticancer activity
por: Fraunhoffer, Nicolas Alejandro, et al.
Publicado: (2022)

Multi-omics data integration and modeling unravels new mechanisms for pancreatic cancer and improves prognostic prediction
por: Fraunhoffer, Nicolas A., et al.
Publicado: (2022)

Priming therapy by targeting enhancer-initiated pathways in patient-derived pancreatic cancer cells
por: Fraunhoffer, Nicolas A., et al.
Publicado: (2023)

Dissecting the Anticancer Mechanism of Trifluoperazine on Pancreatic Ductal Adenocarcinoma
por: Huang, Can, et al.
Publicado: (2019)

Identification of germ cell-specific VASA and IFITM3 proteins in human ovarian endometriosis
por: Fraunhoffer, Nicolas A., et al.
Publicado: (2015)

Expression of POU2F3 Transcription Factor Control Inflammation, Immunological Recruitment and Metastasis of Pancreatic Cancer in Mice
por: Bintz, Jennifer, et al.
Publicado: (2020)

Induction of Apoptosis in Human Pancreatic Cancer Stem Cells by the Endoplasmic Reticulum-Targeted Alkylphospholipid Analog Edelfosine and Potentiation by Autophagy Inhibition
por: Gajate, Consuelo, et al.
Publicado: (2021)

Long-term apoptosis-related protein expression in the diabetic mouse ovary
por: Fraunhoffer, Nicolas A., et al.
Publicado: (2018)

Exploring the Complementarity of Pancreatic Ductal Adenocarcinoma Preclinical Models
por: Hoare, Owen, et al.
Publicado: (2021)

Pancreatic Cancer Organoids for Determining Sensitivity to Bromodomain and Extra-Terminal Inhibitors (BETi)
por: Bian, Benjamin, et al.
Publicado: (2019)

Metabolomic profiling of pancreatic adenocarcinoma reveals key features driving clinical outcome and drug resistance
por: Kaoutari, Abdessamad El, et al.
Publicado: (2021)

Pancreatic Cancer Heterogeneity Can Be Explained Beyond the Genome
por: Juiz, Natalia Anahi, et al.
Publicado: (2019)

Emerging epigenomic landscapes of pancreatic cancer in the era of precision medicine
por: Lomberk, Gwen, et al.
Publicado: (2019)

Pancreatic ductal adenocarcinoma ubiquitination profiling reveals specific prognostic and theranostic markers
por: El Kaoutari, Abdessamad, et al.
Publicado: (2023)

Relevance of biopsy-derived pancreatic organoids in the development of efficient transcriptomic signatures to predict adjuvant chemosensitivity in pancreatic cancer
por: Nicolle, R., et al.
Publicado: (2021)

Upcoming Revolutionary Paths in Preclinical Modeling of Pancreatic Adenocarcinoma
por: Swayden, Mirna, et al.
Publicado: (2020)

Pancreatic cancer resistance conferred by stellate cells: looking for new preclinical models
por: Che, Pei Pei, et al.
Publicado: (2020)

Patient‐derived organoids in cellulosic sponge model chemotherapy response of metastatic colorectal cancer
por: Xu, Yanjie, et al.
Publicado: (2021)

Blood culture of Brucella, challenges and limitations
por: Hajia, Massoud
Publicado: (2018)

Targeting CD44 as a novel therapeutic approach for treating pancreatic cancer recurrence
por: Molejon, Maria Inés, et al.
Publicado: (2015)

Redox-sensitive TP53INP1 SUMOylation as an oxidative stress sensor to activate TP53
por: Bonacci, Thomas, et al.
Publicado: (2014)

Modeling tumor development and metastasis using paired organoids derived from patients with colorectal cancer liver metastases
por: Li, He, et al.
Publicado: (2020)

DNA Methylation of PI3K/AKT Pathway-Related Genes Predicts Outcome in Patients with Pancreatic Cancer: A Comprehensive Bioinformatics-Based Study
por: Faleiro, Inês, et al.
Publicado: (2021)

Inhibition of glutathione metabolism can limit the development of pancreatic cancer
por: Cai, Pei-Yuan, et al.
Publicado: (2022)

Implementing biological markers as a tool to guide clinical care of patients with pancreatic cancer
por: Iovanna, Juan
Publicado: (2020)

Human Brain Organoids-on-Chip: Advances, Challenges, and Perspectives for Preclinical Applications
por: Castiglione, Héloïse, et al.
Publicado: (2022)

Generation of Pancreatic Organoid-Derived Isografts
por: D’Agosto, Sabrina, et al.
Publicado: (2020)

Strengths and limitations of new artificial intelligence tool for rare disease epidemiology
por: Lapidus, David
Publicado: (2023)

Organoids of epithelial ovarian cancer as an emerging preclinical in vitro tool: a review
por: Dumont, Sander, et al.
Publicado: (2019)

Infantile spasms and COVID-19: Challenges and solutions in resource-limited settings
por: Sinha, Rahul, et al.
Publicado: (2020)

A Challenge to Healthy Aging: Limited Social Participation in Old Age
por: Leung, Angela YM, et al.
Publicado: (2021)

Generation of macrophage containing alveolar organoids derived from human pluripotent stem cells for pulmonary fibrosis modeling and drug efficacy testing
por: Heo, Hye-Ryeon, et al.
Publicado: (2021)

Preclinical testing of oncolytic adenovirus sensitivity in patient-derived tumor organoids
por: Pascual-Sabater, Silvia, et al.
Publicado: (2021)

Preclinical investigation of patient-derived cervical cancer organoids for precision medicine
por: Seol, Hyang Sook, et al.
Publicado: (2022)

Prognostic significance of circulating PD-1, PD-L1, pan-BTN3As, BTN3A1 and BTLA in patients with pancreatic adenocarcinoma
por: Bian, Benjamin, et al.
Publicado: (2019)

Establishment and identification of organoids from human circulating colorectal cancer cells
por: Zhang, Long, et al.
Publicado: (2020)

Optimizing individualized treatment strategy based on breast cancer organoid model
por: Pan, Bo, et al.
Publicado: (2021)

Pancreatic cancer derived 3D organoids as a clinical tool to evaluate the treatment response
por: Shukla, Hem D, et al.
Publicado: (2023)

E2F signature is predictive for the pancreatic adenocarcinoma clinical outcome and sensitivity to E2F inhibitors, but not for the response to cytotoxic-based treatments
por: Lan, Wenjun, et al.
Publicado: (2018)

A glycosyltransferase gene signature to detect pancreatic ductal adenocarcinoma patients with poor prognosis
por: Mohamed Abd-El-Halim, Yousra, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_m0kqe6gq75ois1f1pm1uqjucoc